**Mantle cell lymphoma-like solitary polypoid tumor of the esophagus: a case report**

Takahiro Mori¹*, Takuya Komeno² and Haruo Ohtani³

Address: ¹Department of Surgery, ²Department of Hematology and ³Department of Pathology, National Hospital Organization Mito Medical Center, 280 Sakuranosato, Ibaraki, 311-3193 Japan

Email: TM* - tamori@m.tains.tohoku.ac.jp; TK - t.komeno.d@mn.hosp.go.jp; HO - hohtani@mito.hosp.go.jp

* Corresponding author

Published: 15 May 2009

Received: 23 October 2008

Accepted: 23 February 2009

Cases Journal 2009, 2:6646 doi: 10.1186/1757-1626-2-6646

This article is available from: http://casesjournal.com/casesjournal/article/view/6646

© 2009 Mori et al; licensee Cases Network Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Abstract**

**Introduction:** Primary mantle cell lymphoma of the esophagus is quite rare, and we report here a case of a submucosal polypoid tumor of the esophagus that was pathologically similar, but not identical, to mantle cell lymphoma.

**Case presentation:** A 66-year-old man underwent surgery in our hospital for a submucosal tumor of the esophagus. Histopathologically, the submucosal tumor uniformly showed a vague, nodular pattern composed of a regular proliferation of CD3-CD10-CD20+CD79a+bcl2+ small lymphoid cells with islands of abortive CD10+Ki67+ germinal centers, without evidence of marginal zone formation or lymphoepithelial lesions. These features were consistent with mantle cell lymphoma. However, the proliferating cells weakly expressed the D-type cyclins, IgD and IgM. The tumor was diagnosed as a "mantle cell lymphoma-like tumor". Postoperative examination confirmed no tumour involvement in other organs. The patient was treated with rituximab postoperatively and has been disease free for more than 28 months after surgery.

**Conclusion:** The present case might be regarded as a "hyperplastic change of the mantle zone" without the molecular features of mantle cell lymphoma, a case that adds to the limited clinicopathological data on B-lymphoproliferative diseases of the esophagus.

---

**Introduction**

The esophagus is the least common site of involvement of lymphoma in the digestive tract, accounting for less than 1% of lymphoma patients. Primary esophageal lymphomas are usually large B-cell types or low-grade B-cell mucosa-associated lymphoid tissue (MALT) [1]. Furthermore, primary mantle cell lymphoma (MCL) of the esophagus has not been reported, only a case of MCL arising in Barrett’s dysplasia [2]. Here we report an esophageal polypoid tumor that resembles MCL but lacks critical MCL features.

**Case presentation**

A 66-year-old Japanese male underwent upper gastrointestinal endoscopy by his practitioner for complaints of dysphagia, which revealed an esophageal submucosal tumor. He was referred to the National Hospital...
Organization Mito Medical Center in 2006 for treatment. He did not complain of fever, weight loss, or night sweating. On admission, physical examination revealed no remarkable features; the liver, spleen, and superficial nodes were not palpable. His laboratory data showed no abnormalities except a 10-year history of abnormal glucose tolerance treated by his primary physician. No elevated tumor markers or autoimmune antibodies were observed. A barium esophagogram, CT, and upper GI endoscope showed an esophageal submucosal polypoid lesion at the cervical esophagus (Figure 1). Its location close to the esophageal orifice and large size (4 × 2 cm) made an endoscopic resection technically difficult, and the patient was enrolled in the Department of Surgery. As the tumor was endoscopically diagnosed as benign leiomyoma or lipoma, we decided to perform a tumor resection because of the patient’s complaints of dysphagia and because the cervical esophagus is relatively approachable compared with the thoracic esophagus, even without pathological diagnosis. The tumor was removed through a cervical esophagotomy under a cervical collar incision.

The tumor macroscopically showed a submucosal polypoid appearance (Figure 2A). Resected tissue was fixed in 20% formalin, embedded in paraffin, and routinely stained with hematoxylin and eosin, followed by immunohistochemical analyses with monoclonal antibodies, as summarized in Table 1 (supplement). The tumor was composed of multiple, vague nodules (Figure 2A, 2B) that contained abortive CD10+Ki67+ germinal centers surrounded by a regular proliferation of CD3-CD20+CD79a+ bcl2+ small lymphoid cells without immunoblastic large cells (Figure 2C). These areas corresponded to the mantle zone, with no definite formation of the marginal zone observed. No lymphoepithelial lesions (intraepithelial infiltration of neoplastic B-cells with architectural distortion of epithelial structures) were observed, but it showed a typical mantle cell pattern, which was further supported by a sparse distribution of CD21+ follicular dendritic cells (FDCs) next to a dense distribution of FDC in the germinal centers (Figure 3) and negativity for MUM1 protein (approximately 1%, data not shown) [3]. We then examined the chromosomal rearrangement involving IgH and Bcl1 by fluorescence in situ hybridization. In brief, DNA was hybridized with Vysis® LSI® IGH/CCND1 Rearrangement probes (ABBOTT, Wiesbaden, Germany), as described previously [4]. The IgH-Bcl1 chimera was observed in only 1% of examined cells (2.8%, with 0.8% standard deviation).
deviation, in 10 healthy volunteers). Proliferating cells stained for cyclin D1, D2, or D3 only sporadically (1–2%) without expressing IgD or IgM (data not shown). We noted infiltration by CD5+ T cells, but the majority of proliferating cells were negative for CD5 (Figure 3). This pattern was also similar to the mantle zone of the normal lymphoid tissue (Figure 3).

The patient experienced a good post-operative course, and was enrolled in the Department of Hematology. Lymphoma metastasis was evaluated by a whole body CT scan, PET-CT, bone marrow examination, Ga-scintigram, and total colonoscopy, but no other sites were involved. The diagnosis was stage IAE, and rituximab was given as adjuvant chemotherapy. This patient has been disease free for more than 28 months after surgery.

**Discussion**

Primary esophageal lymphoma is rare, with no MCL reported except a case in cardiac-type glandular tissue replacement of the lower esophagus [1, 2, 5–7]. This case, reported by Reyes, contains the typical molecular features of MCL, CD5 staining, cyclin D1 staining, and chromosomal translocation [t(11;14)(q13;q32)] [2]. However, this case arose in cardiac-type glandular tissue replacing the lower oesophagus, not in squamous epithelial tissue. Furthermore, MCL could have originated in the herniated subcardial region of the stomach, because the diagnosis was obtained from biopsies and the presence of a proper esophageal gland was not confirmed.

MALT lymphoma can arise in the esophagus. Hosaka and colleagues showed that three cases previously reported as a
### Table 1. List of antibodies used in this study

| Antibodies for | Species | Sources | Clones | Final dilution | Heat antigen retrieval |
|---------------|---------|---------|--------|--------------|-----------------------|
| CD3           | mouse Mab | Dako    | F7.2.38 | 1:40, 6 mg/ml | T/E, 95C, 60 min      |
| CD5           | mouse Mab | Novocastra | 4C7    | 1:100       | T/E, 95C, 60 min     |
| CD10          | mouse Mab | Novocastra | S6C6   | 1:100       | T/E, 95C, 60 min     |
| CD20          | mouse Mab | Dako    | L26    | 1:400, 1 mg/ml | none                 |
| CD21          | mouse Mab | Dako    | IF8    | 1:50, 7 mg/ml | Dako S1700, 95C, 60min |
| CD79a         | mouse Mab | Nichirei| JCB117  | 1:150       | T/E, 95C, 60 min     |
| bcl-2         | mouse Mab | Dako    | 124    | 1:100, 2.6 mg/ml | T/E, 95C, 60 min     |
| MUM1 protein  | mouse Mab | Dako    | MUM1p  | 1:100, 7.5 mg/ml | T/E, 95C, 60 min     |
| cyclin D1     | rabbit Mab | Nichirei| SP4    | 1:25        | T/E, 95C, 60 min     |
| cyclin D2     | rabbit Pab | Santa Cruz | (sc-593) | 1:100, 2ug/ml | T/E, 95C, 60 min   |
| cyclin D3     | mouse Mab | Progen  | DCS-22 | undiluted   | T/E, 95C, 60 min     |
| IgD           | rabbit Pab | Dako    | A0093  | 1:1500      | RT, 30 min           |

Mab, monoclonal antibody. Pab, polyclonal antibody. RT, room temperature. T/E, 10mM Tris HCl buffer/1mM EDTA, pH9.0. Dako, Glustrup, Denmark. Novocastra, Benton Lane, UK. Nichirei, Tokyo, Japan. Santa Cruz Biotechnology, Santa Cruz, CA. Progen Biotechnik, Heidelberg, Germany.

**Figure 3.** Immunohistochemical analyses of the tumor. CD20-positive lymphoid cells surround abortive CD10-positive germinal centers. Scale, 200 μm or 50 μm, is indicated by bars in CD20 or CD10, respectively. About 10-20% of proliferating cells were CD5 positive lymphoid cells (T-cells), but the vast majority were not. CD21-positive follicular dendritic cells were structurally aligned around germinal centers. The germinal center is indicated by GC and dotted circles with a scale bar of 50 μm. Immunohistochemical analyses by cyclin D1, with a scale bar of 50 μm.
B-cell type non-Hodgkin’s lymphoma might be MALT lymphomas [1]. The differential diagnosis of malignant lymphoma could improve with endoscopic mucosal resection, which obtains a greater amount of tissue than conventional biopsies. Our case showed recurring proliferation of small lymphocytes, but no large cells, surrounding abortive germinal centers. This indicates proliferation of the mantle zone but not the marginal zone. For differential diagnosis, we first need to consider extranodal marginal zone lymphoma (MALT lymphoma). However, the marginal zone typically seen in MALT lymphoma was not present here [1], nor was there a lymphoepithelial lesion. Therefore, we excluded MALT lymphoma. We also need to consider Castleman disease, which includes a hyaline vascular type and a plasma cell type [8, 9]. The germinal center here lacked the characteristic vasculature with a hyalinized wall, and plasma cell infiltration was not observed in the whole areas. These pathological findings prompted us to exclude Castleman’s disease.

Although this case resembled MCL, it lacked the immunostaining and molecular features typical for MCL, including weak expression of cyclins D1, D2, D3, CD5, IgD, or IgM. According to the WHO classification 4th edition, cyclin-D1-negative MCL should overexpress cyclin D2 or D3, as confirmed by gene expression profiles [10]. In addition, MCL prognosis is not favourable, with the vast majority of MCL patients not curable long-term [11]. The current case has been disease free for more than 28 months, suggesting that this case clinically does not fit typical MCL.

Conclusion
Taken together, the current case has similar histological features to MCL, but does not fit the MCL diagnosis. The present case may be “hyperplasia of the mantle zone without neoplastic transformation,” but this conclusion would require careful follow-up. We also need further clinicopathological data regarding B-cell lymphomas of the esophagus.

List of abbreviations
MALT, Mucosa-associated lymphoid tissue; MCL, Mantle cell lymphoma; CT, Computed tomography; GI, Gastrointestinal; PET-CT, Computed tomography.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
TM was involved in the surgery and was a major contributor in writing the manuscript. TK, as a hematologist, collected the data and was involved in the treatment and patient follow-up. HO performed pathological examination and diagnosis of the tumor, and reviewed the scientific content of the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgements
The authors are grateful to Dr. Takuya Moriya, Kawasaki Medical University, for the IgD/IgM immunostain.

References
1. Hosaka S, Nakamura N, Akamatsu T, Fujisawa T, Ogawa Y, Kiyosawa K, Hidaka E, Ota H, Katsuyama K, Inagaki H: A case of primary low grade mucosa associated lymphoid tissue (MALT) lymphoma of the esophagus. Gut 2002, 51:281-284.
2. Reyes CV: Mantle-cell lymphoma in Barrett esophagus. Gastroenterology and Hepatology 2007, 3:392-395.
3. Tsukamoto N, Ichikawa D, Arakawa Y, Date K, Ueda S, Nakagawa Y, Horii A, Nakamura Y, Abe T, Inazawa J: Frequent deletions of material from chromosome arm 1p in oligodendrogial tumors revealed by double-target fluorescence in situ hybridization and microsatellite analysis. Genes Chrom Cancers 1995, 14:295-300.
4. Chadha KS, Hernandez-Illizaliturri FJ, Javle M: Primary esophageal lymphoma: case series and review of the literature. Dig Dis Sci 2006, 51:77-83.
5. Isaacson PG: Gastrointestinal lymphoma. Hum Pathol 1994, 25(1020-1029.
6. Rosenberg SA, Diamond HD, Jaslowitz B, Craver LF: Lymphosarcoma: a review of 1269 cases. Medicine (Baltimore) 1961, 40:31-84.
7. Castleman B, Iveson L, Menendez VP: Localized mediastinal lymph-node hyperplasia resembling lymphoma. Cancer 1956, 9:822-830.
8. Tsukamoto N, Kojima M, Uchiyama T, Takeuchi T, Karasawa M, Murakami H, Sato S: Primary cutaneous CDS+ marginal zone B-cell lymphoma resembling the plasma cell variant of Castleman’s disease Case report. Jpn J Clin Oncol 1995, 25:106:
9. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gisk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimossa L, Brazel RM, Muller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC, Lymphoma/Leukemia Molecular Profiling Project: Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315-4321.
10. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman, JW (Eds.): World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon, France: IARC, 2008:229-232.